The International Journal of Neuropsychopharmacology
June 9, 2011
Nigel C. Jones, Maya Reddy, Paul M Anderson et al.
A single non-anaesthetic dose of ketamine, a non-competitive NMDA receptor (NMDAR) antagonist with hallucinogenic properties, induces cognitive impairment and psychosis, and aggravates schizophrenia symptoms in patients. In conscious rats an equivalent dose of ketamine induces key features of animal models of acute psychosis, including hyperlocomotor activity, deficits in prepulse inhibition...
Behavioural Brain Research
June 6, 2011
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
Psychopharmacology
June 2011
Anita J Bechtholt-Gompf, Karen L Smith, Catherine S John et al.
In patients, ketamine is a fast-acting antidepressant that can induce long-lasting symptom relief. Similar rapid effects have been reported in rodents, but reports of lasting effects are limited. We sought to extend past findings by examining dose-response curves that overlap with the individual doses previously reported to induce lasting effects in rodents and determining whether effects...
Psychopharmacology
May 21, 2011
Ketamine perturbs perception of the flow of time in healthy volunteers.
NMR in Biomedicine
May 11, 2011
In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia.
Biological Psychiatry
May 6, 2011
Amy K. Ricke, R. Snook, A. Anand
34 citations
Ms. M is a 42-year-old Caucasian married woman with a history of chronic left gluteal and left leg pain diagnosed as reflex sympathetic dystrophy. She was disabled by refractory symptoms that had failed a number of interventions and required high-dose opioids. Ms. M was otherwise high functioning and had completed a professional degree. The patient elected to undergo experimental IV ketamine...
The International Journal of Neuropsychopharmacology
May 5, 2011
Retracted
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Molecular Psychiatry
April 19, 2011
Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.
Emerging health threats journal
April 15, 2011
Sarbjeet S Kalsi, David M Wood, Paul I Dargan
Ketamine was originally synthesised for use as a dissociative anaesthetic, and it remains widely used legitimately for this indication. However, there is increasing evidence of non-medical recreational use of ketamine, particularly in individuals who frequent the night-time economy. The population-level and sub-population (clubbers) prevalence of recreational use of ketamine is not known but is...
The Journal of Clinical Psychiatry
April 1, 2011
Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
Behavioural Brain Research
March 21, 2011
Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain.
Neuroscience
March 17, 2011
H Kamiyama, M Matsumoto, S Otani et al.
The non-competitive N-methyl-D-aspartate NMDA receptor antagonist ketamine, a dissociative anesthetic capable of inducing analgesia, is known to have psychotomimetic actions, but the detailed mechanisms remain unclear because of its complex properties. The present study elucidated neural mechanisms of the effect of ketamine, at doses that exert psychotomimetic effects without anesthetic and...
Current Neuropharmacology
March 2011
Fang Liu, Merle G. Paule, Syed F. Ali et al.
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used for analgesia and anesthesia in obstetric and pediatric practice. Recent reports indicate that ketamine causes neuronal cell death in developing rodents and nonhuman primates. The present study assessed the potential dose- and time-dependent neurotoxic effects and associated changes in gene expression after ketamine...
Current Neuropharmacology
March 1, 2011
Carlos Venâncio, Ana Magalhães, Luís Antunes et al.
Ketamine is a noncompetitive antagonist of the NMDA-receptors, used as a dissociative anesthetic, presently included in the category of the psychoactive substances known as “club drugs”. Ketamine administration was associated with impaired working memory and increased psychopathological symptoms, but there is a lack of information regarding the effects of chronic sub-anesthetic doses. Adult...
Psychopharmacology
March 1, 2011
M. D. Luca, A. Badiani
RationaleThe abuse of ketamine has been reported to be on the rise over the past 15 years, but its abuse appears to be limited almost exclusively to the context of music and dance settings, indicating a major role of context in modulating its reinforcing effects. We have previously reported that amphetamine, cocaine, and heroin self-administration (SA) in the rat are differentially influenced...
Substance Abuse and Rehabilitation
March 1, 2011
Jih-Heng Li, Vickna Kasinather, Cheung et al.
146 citations
Ketamine, a derivative of phencyclidine that was developed in the 1960s, is an anesthetic and analgesic with hallucinogenic effects. In this paper, the pharmacological and toxicological effects of ketamine are briefly reviewed. Ketamine possesses a wide safety margin but such a therapeutic benefit is somewhat offset by its emergence phenomenon (mind-body dissociation and delirium) and...
Anesthesia & Analgesia
February 25, 2011
Soon Ho Cheong, Kun Moo Lee, Se Hun Lim et al.
29 citations
The use of ketamine may be associated with the recall of unpleasant dreams after sedation. We hypothesized that a positive suggestion before sedation could reduce the incidence of ketamine-induced unpleasant dreams. To test this hypothesis, we randomized 100 patients receiving sedation with ketamine for their procedure into 2 groups with 1 group having an anesthesiologist provide a...
Consciousness and Cognition
February 16, 2011
Leanne K. Wilkins, Todd A. Girard, J. Allan Cheyne
57 citations
Investigation of "out-of-body experiences" (OBEs) has implications for understanding both normal bodily-self integration and its vulnerabilities. Beyond reported associations between OBEs and specific brain regions, however, there have been few investigations of neurochemical systems relevant to OBEs. Ketamine, a drug used recreationally to achieve dissociative experiences, provides a...
Cognitive Neuropsychiatry
February 6, 2011
James W. Moore, Danielle C. Turner, Philip R. Corlett et al.
64 citations
INTRODUCTION: Aberrant experience of agency is characteristic of schizophrenia. An understanding of the neurobiological basis of such experience is therefore of considerable importance for developing successful models of the disease. We aimed to characterise the effects of ketamine, a drug model for psychosis, on sense of agency (SoA). SoA is associated with a subjective compression of the...
Synapse
February 2011
Sherry M Zakhary, Diana Ayubcha, Farah Ansari et al.
Ketamine exerts powerful anesthetic, psychotic, and antidepressant effects in both healthy volunteers and clinically depressed patients. Although ketamine targets particular glutamate receptors, there is a dearth of evidence for additional, alternative molecular substrates for the behavioral actions of this N-methyl-D-aspartate (NMDA) receptor antagonist drug. Here, we provide behavioral and...